| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9044 | 2-Methoxyestradiol Featured | 2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 μM for the inhibition of BPAEC migration. |
|
| DC11607 | JTZ-951(Enarodustat) Featured | A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2. |
|
| DC11608 | JTZ-951 hydrochloride | A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2. |
|
| DC8188 | Daprodustat Featured | Daprodustat(GSK1278863) isa HIF-prolyl hydroxylase inhibitor. |
|
| DC11402 | Desidustat Featured | Desidustat is an inhibitor of HIF hydroxylase. |
|
| DC8195 | FG2216 Featured | FG-2216 is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 uM for PDH2 enzyme; orally bioavailable and induced significant and reversible Epo induction in vivo. |
|
| DC5193 | Roxadustat(FG-4592) Featured | FG-4592 is an HIF αprolyl hydroxylase inhibitor, stabilizes HIF-2 and induces EPO production. |
|
| DC8166 | Molidustat(BAY 85-3934) Featured | Hypoxia-inducible factor prolyl hydroxylase inhibitor |
|
| DC11782 | IDF-11774 Featured | IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC50 of 3.65 μM. |
|
| DC10825 | IOX4 Featured | IOX4 is a potent inhibitor of PHD2 (IC50 = 1.6 nM). |
|
| DC8617 | JNJ-42041935 Featured | JNJ-42041935 is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes. |
|
| DC8447 | KC7F2 Featured | KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study. |
|
| DC12043 | KHS-101 Featured | KHS101 is a selective inducer of neuronal differentiation; induces neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs) by interacting with TACC3 (EC50 ~1 μM). |
|
| DC7683 | ML-228 | ML-228 is a hIF pathway activator (EC50 values are 1.23 and 1.4 μM for HRE gene reporter assay and HIF-1α nuclear translocation assay respectively); acts via chelation of iron, independently of PHD. |
|
| DC8390 | Oltipraz Featured | Oltipraz is a potent Nrf2 activator and a potent inducer of Phase II detoxification enzymes, most notably glutathione-S-transferase (GST). Phase 3. |
|
| DC10464 | PT2385 Featured | PT2385 is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. |
|
| DC9811 | PT2399 Featured | PT2399(PT=2399) is a novel HIF2α Antagonist. |
|
| DC7486 | PX-478 2HCL Featured | PX-478 is an inhibitor of HIF-1a with an IC50 of 20-30μM enhances radiosensitivity of prostate carcinoma cells. |
|
| DC10436 | SYP-5 Featured | SYP-5 is a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. |
|
| DC10339 | Vadadustat Featured | Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia. |
|
| DC28630 | HIF-2α-IN-2 | HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC50 of 16 nM in scintillation proximity assay (SPA). |
|
| DC41030 | 1,4-DPCA ethyl ester Featured | 1,4-DPCA ethyl ester is the ethyl ester of 1,4-DPCA and can inhibit factor inhibiting HIF (FIH). |
|
| DC41831 | TAT-cyclo-CLLFVY | TAT-cyclo-CLLFVY is a selective HIF-1 dimerization inhibitor. TAT-cyclo-CLLFVY blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50=1.3 μM). TAT-cyclo-CLLFVY inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. TAT-cyclo-CLLFVY also reduces tubularization of hypoxic HUVECs. |
|
| DC42072 | Verucopeptin | Verucopeptin is a potent?HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity?by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR)?cancers and can be used for cancer research. |
|
| DC43985 | ENMD-1198 | ENMD-1199 (IRC-110160) is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity, and is suitable for inhibiting HIF-1α and STAT3 in human HCC cells. |
|
| DC44919 | TM6089 | TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector. |
|
| DC44920 | Moracin O | Moracin O is a 2-arylbenzofuran isolated from the Mori Cortex Radicis. Moracin O exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1). Moracin O reduces oxygen-glucose deprivation (OGD)-induced reactive oxygen species (ROS) production. Moracin O has neuroprotective and anti-inflammatory effects. |
|
| DC45793 | TRC160334 | TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury. |
|
| DC45910 | AKB-6899 | AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects. |
|
| DC46311 | TAT-cyclo-CLLFVY TFA | TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM. |
|
